- Home
- FTV vs BBIO Comparison
FTV vs BBIO Comparison
Compare FTV & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTV | BBIO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 14.7B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FTV | BBIO |
|---|---|---|
| Price | $55.64 | $75.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 21 |
| Target Price | $56.64 | ★ $76.24 |
| AVG Volume (30 Days) | ★ 2.9M | 1.8M |
| Earning Date | 02-06-2026 | 10-29-2025 |
| Dividend Yield | ★ 0.43% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $6,260,300,000.00 | $353,780,000.00 |
| Revenue This Year | N/A | $127.64 |
| Revenue Next Year | $3.02 | $78.38 |
| P/E Ratio | $21.59 | ★ N/A |
| Revenue Growth | 36.34 | ★ 62.46 |
| 52 Week Low | $46.34 | $27.23 |
| 52 Week High | $83.32 | $78.44 |
Technical Indicators
Market Signals| Indicator | FTV | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 64.27 | 62.87 |
| Support Level | $54.44 | $75.82 |
| Resistance Level | $55.91 | $78.44 |
| Average True Range (ATR) | 0.85 | 2.20 |
| MACD | -0.02 | -0.24 |
| Stochastic Oscillator | 88.61 | 68.91 |
Price Performance
Historical ComparisonAbout FTV Fortive Corporation
Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.2 billion in revenue in 2024.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.